Kryštof V - Search Results

1

How selective are clinical CDK4/6 inhibitors?

Hendrychová D, Jorda R, Kryštof V. Hendrychová D, et al. Among authors: krystof v. Med Res Rev. 2021 May;41(3):1578-1598. doi: 10.1002/med.21769. Epub 2020 Dec 10. Med Res Rev. 2021. PMID: 33300617 Review.

2

Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.

Otyepka M, Krystof V, Havlícek L, Siglerová V, Strnad M, Koca J. Otyepka M, et al. Among authors: krystof v. J Med Chem. 2000 Jun 29;43(13):2506-13. doi: 10.1021/jm990506w. J Med Chem. 2000. PMID: 10891109

3

Pyrazolo[4,3-d]pyrimidines as new generation of cyclin-dependent kinase inhibitors.

Moravcová D, Krystof V, Havlícek L, Moravec J, Lenobel R, Strnad M. Moravcová D, et al. Among authors: krystof v. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2989-92. doi: 10.1016/s0960-894x(03)00631-0. Bioorg Med Chem Lett. 2003. PMID: 12941318

4

2,6,8,9-tetrasubstituted purines as new CDK1 inhibitors.

Moravec J, Krystof V, Hanus J, Havlícek L, Moravcová D, Fuksová K, Kuzma M, Lenobel R, Otyepka M, Strnad M. Moravec J, et al. Among authors: krystof v. Bioorg Med Chem Lett. 2003 Sep 15;13(18):2993-6. doi: 10.1016/s0960-894x(03)00632-2. Bioorg Med Chem Lett. 2003. PMID: 12941319

5

8-Azapurines as new inhibitors of cyclin-dependent kinases.

Havlicek L, Fuksova K, Krystof V, Orsag M, Vojtesek B, Strnad M. Havlicek L, et al. Among authors: krystof v. Bioorg Med Chem. 2005 Sep 15;13(18):5399-407. doi: 10.1016/j.bmc.2005.06.007. Bioorg Med Chem. 2005. PMID: 15993080

6

Preparation and biological activity of 6-benzylaminopurine derivatives in plants and human cancer cells.

Dolezal K, Popa I, Krystof V, Spíchal L, Fojtíková M, Holub J, Lenobel R, Schmülling T, Strnad M. Dolezal K, et al. Among authors: krystof v. Bioorg Med Chem. 2006 Feb 1;14(3):875-84. doi: 10.1016/j.bmc.2005.09.004. Epub 2005 Oct 7. Bioorg Med Chem. 2006. PMID: 16214355

7

4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

Krystof V, Cankar P, Frysová I, Slouka J, Kontopidis G, Dzubák P, Hajdúch M, Srovnal J, de Azevedo WF Jr, Orság M, Paprskárová M, Rolcík J, Látr A, Fischer PM, Strnad M. Krystof V, et al. J Med Chem. 2006 Nov 2;49(22):6500-9. doi: 10.1021/jm0605740. J Med Chem. 2006. PMID: 17064068

8

Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine.

Paprskárová M, Krystof V, Jorda R, Dzubák P, Hajdúch M, Wesierska-Gadek J, Strnad M. Paprskárová M, et al. Among authors: krystof v. J Cell Biochem. 2009 Jun 1;107(3):428-37. doi: 10.1002/jcb.22139. J Cell Biochem. 2009. PMID: 19308936

9

Pharmacological targeting of CDK9 in cardiac hypertrophy.

Krystof V, Chamrád I, Jorda R, Kohoutek J. Krystof V, et al. Med Res Rev. 2010 Jul;30(4):646-66. doi: 10.1002/med.20172. Med Res Rev. 2010. PMID: 19757441 Review.

10

Cyclin-dependent kinase inhibitors as anticancer drugs.

Krystof V, Uldrijan S. Krystof V, et al. Curr Drug Targets. 2010 Mar;11(3):291-302. doi: 10.2174/138945010790711950. Curr Drug Targets. 2010. PMID: 20210754 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

157 results

Search Page